• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help – ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk

1
  • by alexperjescuadmin
  • in Cardiovascular
  • — 26 Mar, 2007
COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
AudioMedica News
COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-271"/>
Steven Nissen

STEVEN NISSEN, Cleveland Clinic, OH

REFERENCE: N Engl J Med 2007 356
Reporting from: American College of Cardiolgy New Orleans

Two big studies published in the New England Journal of Medicine and presented simultaneously at the American College of Cardiology meeting in New Orleans have shown that two emerging therapies aimed at reducing risks in patients with coronary disease have failed to do so. The president of the ACC, Steven Nissen, talked with Peter Goodwin about the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, in which patients with stable coronary artery disease were randomized to receive optimal medical therapy with or without PCI. He also discussed findings of the ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) study in which the cholesteryl ester transfer protein inhibitor, torcetrapib was found to have adverse effects when used for modifying lipid profiles among coronary patients.

[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070327_steven_nissen.mp3]
Share

Tags: accanginacoronary riskHDLnew england journalsteven nissentherapiestorcetrapibtrial

You may also like...

  • Timothy Brighton Important new role for aspirin: prevention of recurrent thromboembolism: ASPIRE findings 12 Nov, 2012
  • Audio Journal of Cardiovascular Medicine: “COURAGE” Trial Assessed: New Guidelines for Patients with Stable Coronary Disease? Audio Journal of Cardiovascular Medicine: “COURAGE” Trial Assessed: New Guidelines for Patients with Stable Coronary Disease? 6 Apr, 2007
  • AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress 3 Oct, 2013
  • Looking for Atherosclerosis in the Legs Could Save Lives Looking for Atherosclerosis in the Legs Could Save Lives 5 Sep, 2007

1 Comment

  1. Prof.Abdul Maguid Al Ballat says:
    May 21, 2007 at 6:32 am

    Type your comment here.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Bioabsorbable Everolimus-Eluting Stent: 6-Month Angiographic and IVUS Results
  • Next story “ERASE” Trial: Infusions of Reconstituted HDL Treat Atherosclerosis in Patients with Acute Coronary Syndromes
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with…
    • CT Screening Cuts Lung Cancer Deaths 24 Per…
  • Home
  • Cardiovascular
  • COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help – ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.